Literature DB >> 21272667

Micellar nanomedicine of human neuropeptide Y.

Antonina Kuzmis1, Sok Bee Lim, Esha Desai, Eunjung Jeon, Bao-Shiang Lee, Israel Rubinstein, Hayat Onyüksel.   

Abstract

Human neuropeptide Y (NPY) is an important biologics that regulates a multitude of physiological functions and could be amenable to therapeutic manipulations in certain disease states. However, rapid (within minutes) enzymatic degradation and inactivation of NPY precludes its development as a drug. Accordingly, we determined whether self-association of NPY with biocompatible and biodegradable sterically stabilized phospholipid micelles (SSM) improves its stability and bioactivity. We found that in saline NPY spontaneously aggregates; however, in the presence of SSM it self-associates with the micelles as monomers. Three NPY molecules self-associate with 1 SSM at saturation. This process stabilizes the peptide in α-helix conformation, abrogates its degradation by dipeptidyl peptidase-4 and potentiates NPY-induced inhibition of cAMP elaboration in SK-N-MC cells. Collectively, these data indicate that self-association of NPY with SSM stabilizes and protects the peptide in active monomeric conformation, thereby amplifying its bioactivity in vitro. We propose further development of NPY in SSM as a novel, long-acting nanomedicine. FROM THE CLINICAL EDITOR: Human neuropeptide Y (NPY) regulates a multitude of physiological functions and could be amenable to therapeutic manipulations, which is currently limited by its short half life. Self-association of NPY with spherically stabilized micelles (SSM) protects and stabilizes the peptide in active monomeric conformation, thereby amplifying its bioactivity in vitro, enabling future therapeutic considerations.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21272667      PMCID: PMC3100534          DOI: 10.1016/j.nano.2011.01.004

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  46 in total

Review 1.  Are hormones from the neuropeptide Y family recognized by their receptors from the membrane-bound state?

Authors:  Reto Bader; Oliver Zerbe
Journal:  Chembiochem       Date:  2005-09       Impact factor: 3.164

2.  Neuropeptide Y (NPY) cleaving enzymes: structural and functional homologues of dipeptidyl peptidase 4.

Authors:  Nadine Frerker; Leona Wagner; Raik Wolf; Ulrich Heiser; Torsten Hoffmann; Jens-Ulrich Rahfeld; Jutta Schade; Tim Karl; Hassan Y Naim; Marwan Alfalah; Hans-Ulrich Demuth; Stephan von Hörsten
Journal:  Peptides       Date:  2007-01-16       Impact factor: 3.750

3.  Detailed structure of hairy mixed micelles formed by phosphatidylcholine and PEGylated phospholipids in aqueous media.

Authors:  Lise Arleth; Beena Ashok; Hayat Onyuksel; Pappannan Thiyagarajan; Jaby Jacob; Rex P Hjelm
Journal:  Langmuir       Date:  2005-04-12       Impact factor: 3.882

4.  Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets.

Authors:  J C Reubi; M Gugger; B Waser; J C Schaer
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

5.  Changes in neurotransmitter levels and proinflammatory cytokine mRNA expressions in the mice olfactory bulb following nanoparticle exposure.

Authors:  Dai Mitsushima; Shoji Yamamoto; Atsushi Fukushima; Toshiya Funabashi; Takahiro Kobayashi; Hidekazu Fujimaki
Journal:  Toxicol Appl Pharmacol       Date:  2007-09-20       Impact factor: 4.219

Review 6.  A neuropeptide in immune-mediated inflammation, Y?

Authors:  Thomas Prod'homme; Martin S Weber; Lawrence Steinman; Scott S Zamvil
Journal:  Trends Immunol       Date:  2006-03-10       Impact factor: 16.687

7.  NPY Y2 receptor agonist PYY(3-36) inhibits diarrhea by reducing intestinal fluid secretion and slowing colonic transit in mice.

Authors:  Ryuichi Moriya; Takashi Shirakura; Hiroyasu Hirose; Tetsuya Kanno; Jun Suzuki; Akio Kanatani
Journal:  Peptides       Date:  2009-11-17       Impact factor: 3.750

8.  Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration.

Authors:  Xiaoling Gao; Weixing Tao; Wei Lu; Qizhi Zhang; Yan Zhang; Xinguo Jiang; Shoukuan Fu
Journal:  Biomaterials       Date:  2006-02-28       Impact factor: 12.479

9.  Effects of PKA modulation on the expression of neuropeptide Y in rat amygdaloid structures during ethanol withdrawal.

Authors:  Huaibo Zhang; Subhash C Pandey
Journal:  Peptides       Date:  2003-09       Impact factor: 3.750

10.  Suppression of neuroblastoma growth by dipeptidyl peptidase IV: relevance of chemokine regulation and caspase activation.

Authors:  W T Arscott; A E LaBauve; V May; U V Wesley
Journal:  Oncogene       Date:  2008-11-03       Impact factor: 9.867

View more
  7 in total

1.  Human pancreatic polypeptide in a phospholipid-based micellar formulation.

Authors:  Amrita Banerjee; Hayat Onyuksel
Journal:  Pharm Res       Date:  2012-03-08       Impact factor: 4.200

2.  Solubilization of therapeutic agents in micellar nanomedicines.

Authors:  Lela Vuković; Antonett Madriaga; Antonina Kuzmis; Amrita Banerjee; Alan Tang; Kevin Tao; Neil Shah; Petr Král; Hayat Onyuksel
Journal:  Langmuir       Date:  2013-12-09       Impact factor: 3.882

3.  VIP-targeted Cytotoxic Nanomedicine for Breast Cancer.

Authors:  Aparna Dagar; Antonina Kuzmis; Israel Rubinstein; Marin Sekosan; Hayat Onyuksel
Journal:  Drug Deliv Transl Res       Date:  2012-12-01       Impact factor: 4.617

4.  Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis.

Authors:  Varun Sethi; Israel Rubinstein; Antonina Kuzmis; Helen Kastrissios; James Artwohl; Hayat Onyuksel
Journal:  Mol Pharm       Date:  2013-01-23       Impact factor: 4.939

5.  Recent developments in protein and peptide parenteral delivery approaches.

Authors:  Ashaben Patel; Kishore Cholkar; Ashim K Mitra
Journal:  Ther Deliv       Date:  2014-03

6.  Enhancing Specific Disruption of Intracellular Protein Complexes by Hydrocarbon Stapled Peptides Using Lipid Based Delivery.

Authors:  D Thean; J S Ebo; T Luxton; Xue'Er Cheryl Lee; T Y Yuen; F J Ferrer; C W Johannes; D P Lane; C J Brown
Journal:  Sci Rep       Date:  2017-05-11       Impact factor: 4.379

Review 7.  BH3-mimetics: recent developments in cancer therapy.

Authors:  Paul A Townsend; Maria V Kozhevnikova; Olivier N F Cexus; Andrey A Zamyatnin; Surinder M Soond
Journal:  J Exp Clin Cancer Res       Date:  2021-11-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.